A number of other analysts have also recently commented on SAZ. Independent Research set a €89.00 ($109.88) target price on Stada Arzneimittel and gave the stock a neutral rating in a research report on Wednesday. Cfra set a €70.00 ($86.42) target price on Stada Arzneimittel and gave the stock a sell rating in a research report on Monday, March 12th. Warburg Research set a €74.40 ($91.85) target price on Stada Arzneimittel and gave the stock a sell rating in a research report on Friday, March 9th. Finally, Commerzbank set a €66.25 ($81.79) target price on Stada Arzneimittel and gave the stock a sell rating in a research report on Wednesday, December 20th. Five research analysts have rated the stock with a sell rating and two have assigned a hold rating to the stock. Stada Arzneimittel currently has an average rating of Sell and a consensus target price of €73.49 ($90.73).
Shares of Stada Arzneimittel (ETR SAZ) opened at €83.90 ($103.58) on Friday. Stada Arzneimittel has a 52-week low of €53.41 ($65.94) and a 52-week high of €90.24 ($111.41). The company has a market capitalization of $5,270.00 and a PE ratio of 61.24.
About Stada Arzneimittel
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux.
Receive News & Ratings for Stada Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stada Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.